Lapatinib Plus Trametinib in KRAS Mutant NSCLC
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2173655
下载链接
链接失效反馈官方服务：
资源简介：
This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with trametinib in patients with metastatic KRASm and PIK3CA wild-type (PIK3CAwt) non-small cell lung cancer (NSCLC). Part B is designed to perform a randomized comparison of the lapatinib-trametinib combination versus standard of care therapy in patients with metastatic KRASm/PIK3CAwt NSCLC.
创建时间：
2014-10-15
